Non-alcoholic steatohepatitis with normal aminotransferase values

Table 6 Comparison between patients with NASH and without NASH according to anthropometric, clinical and laboratory features n (%)

	All NAFLD patients		P
	Patients with NASH (n = 23)	Patients without NASH (n = 11)
Age (yr)	51.17 ± 5.11	48.82 ± 9.05	> 0.05
Gender: male/female	7/16 (30.4/69.6)	4/7 (36.4/63.6)	> 0.05
Hepatomegaly	7 (29.2)	4 (36.4)	> 0.05
Obesity (BMI ≥ 30)	23 (100)	8 (72.7)	< 0.05
Waist/hip ratio	17 (63.6)	7 (73.9)	> 0.05
Systolic blood pressure (mmHg)1	120 (110-180)	130 (110-180)	> 0.05
Diastolic blood pressure (mmHg)1	70 (65-110)	70 (60-120)	> 0.05
Hypertension	10 (45.5)	6 (60)	> 0.05
HDL-Cholesterol (mg/dL)	44.09 ± 5.77	46.91 ± 9.66	> 0.05
Low-HDL level	13 (56.5)	4 (36.4)	> 0.05
Triglycerides (mg/dL)	146.61 ± 74.43	174.18 ± 83.85	> 0.05
Hypertriglyceridemia	10 (43.5)	5 (45.5)	> 0.05
Fasting glucose (mg/dL)1	102.33 (73-195)	100 (83-125)	> 0.05
Diabetes	6 (26.1)	2 (18.2)	> 0.05
Impaired glucose tolerance	9 (39.1)	1 (9.1)	> 0.05
Fasting insulin (&mgr;U/mL)1	13.44 (4.76-47.3)	16.60 (6-21.80)	> 0.05
Insulin resistance-HOMA-IR	13 (81.3)	6 (66.7)	> 0.05
AST (U/L)1	40 (14-92)	51 (14-78)	> 0.05
ALT (U/L)1	67 (15-158)	82 (13-166)	> 0.05
GGT (U/L)1	33 (15-119)	43 (15-426)	> 0.05
ALP (U/L)1	81 (52-152)	81 (51-154)	> 0.05
AST/ALT > 1	4 (17.3)	2 (18.1)	> 0.05
Metabolic syndrome	18 (78.3)	9 (81.8)	> 0.05

¹Data expressed as median (minimum-maximum); BMI: Body mass index; HOMA: Homeostasis model assessment; HDL: High-density lipoprotein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma glutamyl transpeptidase. There was a significant difference between patients with or without NASH according to the presence of obesity only.